Cigna Corporation (CI)

FairStock Score: 71/100 — STEADY

Key Financials

Strengths

• Strong free cash flow generation of $9.8B provides dividend and buyback capacity
• Diversified revenue streams across healthcare plans and specialty services reduce single-product risk
• Low beta of 0.23 indicates defensive characteristics in portfolio
• Reasonable leverage at 0.75x D/E provides financial flexibility
• Scale advantages with 65,669 employees and $72.4B quarterly revenue

Concerns

• Valuation is stretched at 111% above Graham Number with negative margin of safety
• Dangerously low Altman Z-Score of 1.26 signals potential financial stress
• ROCE of 4.09% well below cost of capital indicates poor capital allocation
• Net margin collapsed to 1.71% in Q4—unsustainable profitability in core business

AI Analysis

Cigna presents a classic insurance paradox: solid operational cash generation masking significant valuation concerns. At $271.63 with a Graham Number of $128.57, we're paying 2.1x intrinsic value—a margin of safety that Graham would find deeply troubling. The business itself shows competence: $9.8B in free cash flow, a 15% ROE, and a fortress balance sheet with reasonable leverage at 0.75x debt-to-equity. The low beta of 0.23 suggests stability, and the 8% FCF yield indicates genuine cash-generating capability. However, I'm concerned about business quality deterioration. The 1.26 Altman Z-Score sits dangerously close to distress territory, while the microscopic 1.71% net margin in Q4 2025 reveals razor-thin profitability despite massive scale. The Piotroski F-Score of 6/9 suggests weakening financial fundamentals. Cigna's ROCE of just 4.09%—far below our cost of capital—indicates the company struggles to generate returns on reinvested earnings. The healthcare insurance industry remains structurally challenged: regulated margins, rising medical costs, and intense competition create a moat that's more mirage than moat. The FairStock Score of 58/100 reflects this tension between cash flow and valuation. While Evernorth's diversified services segment offers some differentiation, the core insurance business is commodity-like. I'd need to see Cigna trading below $150—closer to the Graham Number—to justify a position. At current prices, the margin of safety has evaporated entirely.

Bull Case

Cigna's substantial free cash flow of $9.8B provides a reliable return vehicle for shareholders through buybacks and dividends. Consolidation in healthcare could unlock pricing power and margin expansion, particularly if the company successfully integrates Evernorth services with its core insurance offerings.

Bear Case

Rising medical costs and regulatory pressure could compress margins further below 1.71%, while increasing competition from UnitedHealth and Anthem threatens market share. If the Altman Z-Score deteriorates further, refinancing risk and covenant violations could trigger a significant valuation reset.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer